演題抄録

一般演題 (示説)

開催概要
開催回
第54回・2016年・横浜
 

Efficacy and safety of tadalafil (CIALIS) in men with erectile dysfunction secondary to radical prostatectomy or hormone-radiotherapy in patients with prostate cancer

演題番号 : P25-8

[筆頭演者]
Mermershtain Wilmosh:1 
[共同演者]
Mashal Abdallah:2、Gusakova Irina:1、Ariad Samuel:1、Keren Rouvinov:1

1:Soroka University Medical Center, Israel・Department of Oncology・Onco - Urology Service、2:Soroka University Medical Center・Department of Family Medicine

 

Aim. The purpose of this study was to estimate the tadalafil (Cialis) efficacy and safety in male patients with erectile dysfunction secondary to radical prostatectomy or hormone-radiotherapy therapy in patients with prostate cancer.
Patients / Methods: The study included 30 patients with confirmed prostate adenocarcinoma. Ten patients underwent radical prostatectomy, and 20 patients treated by concomitant TAB and 3DCRT. The median age was 68 years. The treatment with Tadalafil 20mg every 72 hours was initiated at 1-3 months after prostatectomy or 3DCRT. Subsequently, Tadalafil scheduling could be adjusted to a patient needs. Data were collected using the International Index of Erectile Function (IIEF) questionnaire.
Results: Tadalafil significantly improved ED for 60% according to questionnaires. Improvent of ED reported in 70% of the pateints who started Tadalafil at 1 monthts after RP or 3DCRT, compared to 30% in those whose therapy was initiated at longer interval.
Conclusions: To our experience, Tadalafil (20 mg) improved erectile function and was well tolerated by men with ED secondary to radical prostatectomy and concomitant hormono- radiation therapy in patient with prostate cancer. Early iniation of Tadalafil may be predictive for better functional outcome.

キーワード

臓器別:前立腺・男性生殖器

手法別:臨床試験

前へ戻る